PDS Biotechnology Corporation (PDSB) vs Xilio Therapeutics, Inc. (XLO)
A side-by-side comparison of PDS Biotechnology Corporation and Xilio Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
PDSB
PDS Biotechnology Corporation
$1.07HealthcareDelayed quote: Oct 6, 2026, 3:55 PM EDT
XLO
Xilio Therapeutics, Inc.
$9.09HealthcareDelayed quote: Oct 6, 2026, 3:55 PM EDT
Total return — PDSB vs XLO
growth of $100 · dividends reinvested · last 5yPDSB -89.7% (-36.5%/yr)XLO -95.9% (-47.3%/yr)PDSB compounded faster over this window
PDSB XLO
PDSB vs XLO: by the numbers
- •XLO is the larger company ($60M vs $60M market cap).
- •Both run net losses; PDSB's is the smaller (0.00% vs -34.06% net margin).
Metrics side by side
Valuation
| Metric | PDSB | XLO |
|---|---|---|
| P/S ratio | N/A | 0.93 |
| P/B ratio | N/A | 0.83 |
Profitability
| Metric | PDSB | XLO |
|---|---|---|
| Gross margin | 0.00% | 99.46% |
| Operating margin | 0.00% | -95.92% |
| Net margin | 0.00% | -34.06% |
| ROE | N/A | -30.21% |
| ROIC | -3699.99% | -26.13% |
Growth (annualized)
| Metric | PDSB | XLO |
|---|---|---|
| Total return CAGR (5Y) | -39.13% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.